Actively Recruiting
Phase 12 Study of Selinexor With ICE Chemotherapy and Dexamethasone for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma With Secondary CNS Involvement
Led by Samsung Medical Center · Updated on 2026-04-23
37
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Secondary central nervous system CNS involvement in patients with B-cell non-Hodgkin lymphoma, especially diffuse large B-cell lymphoma DLBCL and transformed follicular lymphoma FL, is a rare but serious condition with limited treatment options. This phase III trial investigates the safety and effectiveness of selinexor, an oral drug that restores tumor suppressor functions, combined with ifosfamide, carboplatin, etoposide ICE regimen, and dexamethasone for patients with relapsed or refractory B-cell NHL involving the CNS. The study aims to improve outcomes where current salvage therapies have limited success.
CONDITIONS
Brief Title
Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma
Research Team
S
Seok Jin Kim, MD., PhD
K
Ka Young Song, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
